JP6847828B2 - 新規なカリウムチャネルブロッカー及び自己免疫疾患の治療におけるそれらの使用 - Google Patents
新規なカリウムチャネルブロッカー及び自己免疫疾患の治療におけるそれらの使用 Download PDFInfo
- Publication number
- JP6847828B2 JP6847828B2 JP2017508102A JP2017508102A JP6847828B2 JP 6847828 B2 JP6847828 B2 JP 6847828B2 JP 2017508102 A JP2017508102 A JP 2017508102A JP 2017508102 A JP2017508102 A JP 2017508102A JP 6847828 B2 JP6847828 B2 JP 6847828B2
- Authority
- JP
- Japan
- Prior art keywords
- shk
- analog
- seq
- amino acid
- analog according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000023275 Autoimmune disease Diseases 0.000 title claims description 33
- 239000003450 potassium channel blocker Substances 0.000 title description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 62
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 51
- 229920001184 polypeptide Polymers 0.000 claims description 44
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 34
- 210000004027 cell Anatomy 0.000 claims description 33
- 238000006467 substitution reaction Methods 0.000 claims description 28
- 239000003053 toxin Substances 0.000 claims description 16
- 231100000765 toxin Toxicity 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 12
- 230000001404 mediated effect Effects 0.000 claims description 10
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 6
- 108091033319 polynucleotide Proteins 0.000 claims description 6
- 239000002157 polynucleotide Substances 0.000 claims description 6
- 102000040430 polynucleotide Human genes 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 238000010367 cloning Methods 0.000 claims description 4
- 239000013599 cloning vector Substances 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940127557 pharmaceutical product Drugs 0.000 claims 2
- 101100330292 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cys-12 gene Proteins 0.000 claims 1
- 101100498071 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cys-17 gene Proteins 0.000 claims 1
- 101100386053 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cys-3 gene Proteins 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 101000994669 Homo sapiens Potassium voltage-gated channel subfamily A member 3 Proteins 0.000 description 77
- 102100034355 Potassium voltage-gated channel subfamily A member 3 Human genes 0.000 description 56
- 235000001014 amino acid Nutrition 0.000 description 52
- 150000001413 amino acids Chemical class 0.000 description 44
- 108091006146 Channels Proteins 0.000 description 27
- 238000000034 method Methods 0.000 description 21
- 201000006417 multiple sclerosis Diseases 0.000 description 15
- 206010039073 rheumatoid arthritis Diseases 0.000 description 13
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 11
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 11
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 11
- 230000003993 interaction Effects 0.000 description 10
- 238000000329 molecular dynamics simulation Methods 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 9
- 150000007942 carboxylates Chemical class 0.000 description 8
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000004007 reversed phase HPLC Methods 0.000 description 6
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- -1 citrulin Chemical compound 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 125000005647 linker group Chemical group 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000004088 simulation Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 206010062016 Immunosuppression Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000002438 mitochondrial effect Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 238000010188 recombinant method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- OVJBOPBBHWOWJI-FYNXUGHNSA-N (2S)-2-[[(2S)-1-[(2S)-2-[[(aS,1R,3aS,4S,10S,16S,19R,22S,25S,28S,34S,37S,40R,45R,48S,51S,57S,60S,63S,69S,72S,75S,78S,85R,88S,91R,94S)-40-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3S)-2-[[(2S,3S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]-25,48,78,88,94-pentakis(4-aminobutyl)-a-(2-amino-2-oxoethyl)-22,63,72-tris(3-amino-3-oxopropyl)-69-benzyl-37-[(1R)-1-hydroxyethyl]-34,60-bis(hydroxymethyl)-51,57,75-trimethyl-16-(2-methylpropyl)-3a-(2-methylsulfanylethyl)-2a,3,5a,9,15,18,21,24,27,33,36,39,47,50,53,56,59,62,65,68,71,74,77,80,87,90,93,96,99-nonacosaoxo-7a,8a,42,43,82,83-hexathia-1a,2,4a,8,14,17,20,23,26,32,35,38,46,49,52,55,58,61,64,67,70,73,76,79,86,89,92,95,98-nonacosazahexacyclo[43.35.25.419,91.04,8.010,14.028,32]nonahectane-85-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-imidazol-5-yl)propanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](N)[C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]3CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CO)NC(=O)[C@@H](NC1=O)[C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N3)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC2=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O OVJBOPBBHWOWJI-FYNXUGHNSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000242759 Actiniaria Species 0.000 description 3
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 101000997261 Centruroides margaritatus Potassium channel toxin alpha-KTx 2.2 Proteins 0.000 description 3
- 108010023798 Charybdotoxin Proteins 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 108010027296 Kv1.3 Potassium Channel Proteins 0.000 description 3
- 102000018706 Kv1.3 Potassium Channel Human genes 0.000 description 3
- 101100426589 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) trp-3 gene Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 description 3
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- MJOGHHIGMBYMHS-REOHCLBHSA-N (2s)-2-(aminooxyamino)-3-hydroxypropanoic acid Chemical compound NON[C@@H](CO)C(O)=O MJOGHHIGMBYMHS-REOHCLBHSA-N 0.000 description 2
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- SNLOIIPRZGMRAB-UHFFFAOYSA-N 2-azaniumyl-3-(1h-pyrrolo[2,3-b]pyridin-3-yl)propanoate Chemical compound C1=CC=C2C(CC(N)C(O)=O)=CNC2=N1 SNLOIIPRZGMRAB-UHFFFAOYSA-N 0.000 description 2
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 2
- 102000005367 Carboxypeptidases Human genes 0.000 description 2
- 108010006303 Carboxypeptidases Proteins 0.000 description 2
- 208000014997 Crohn colitis Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 102100029727 Enteropeptidase Human genes 0.000 description 2
- 108010013369 Enteropeptidase Proteins 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 102000001398 Granzyme Human genes 0.000 description 2
- 108060005986 Granzyme Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- DCWXELXMIBXGTH-QMMMGPOBSA-L O(4)-phosphonato-L-tyrosine(2-) Chemical group [O-]C(=O)[C@@H]([NH3+])CC1=CC=C(OP([O-])([O-])=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-L 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 150000001408 amides Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 239000002981 blocking agent Substances 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- CNVQLPPZGABUCM-LIGYZCPXSA-N ctx toxin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H]3CSSC[C@@H](C(N[C@@H](CC=4C5=CC=CC=C5NC=4)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC3=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CO)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3NC=NC=3)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N2)C(C)C)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC1=O)=O)CCSC)C(C)C)[C@@H](C)O)NC(=O)[C@H]1NC(=O)CC1)C1=CC=CC=C1 CNVQLPPZGABUCM-LIGYZCPXSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 238000001425 electrospray ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 229960003330 pentetic acid Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002795 scorpion venom Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 description 1
- LGVJIYCMHMKTPB-BKLSDQPFSA-N (2s)-2-amino-3-hydroxypentanoic acid Chemical compound CCC(O)[C@H](N)C(O)=O LGVJIYCMHMKTPB-BKLSDQPFSA-N 0.000 description 1
- VAZDOLJKYLURLC-QMMMGPOBSA-N (2s)-3-phenyl-2-(phosphonoamino)propanoic acid Chemical compound OP(=O)(O)N[C@H](C(=O)O)CC1=CC=CC=C1 VAZDOLJKYLURLC-QMMMGPOBSA-N 0.000 description 1
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- FRYOUKNFWFXASU-UHFFFAOYSA-N 2-(methylamino)acetic acid Chemical compound CNCC(O)=O.CNCC(O)=O FRYOUKNFWFXASU-UHFFFAOYSA-N 0.000 description 1
- RUVRGYVESPRHSZ-UHFFFAOYSA-N 2-[2-(2-azaniumylethoxy)ethoxy]acetate Chemical compound NCCOCCOCC(O)=O RUVRGYVESPRHSZ-UHFFFAOYSA-N 0.000 description 1
- DGRJZSGHEKZYHP-UHFFFAOYSA-N 2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]acetic acid Chemical compound NCCOCCOCCOCC(O)=O DGRJZSGHEKZYHP-UHFFFAOYSA-N 0.000 description 1
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 description 1
- UACSRZWSADEYPK-UHFFFAOYSA-N 2-[4,7-bis[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]-1,4,7-triazonan-1-yl]acetic acid Chemical compound CC(C)(C)OC(=O)CN1CCN(CC(O)=O)CCN(CC(=O)OC(C)(C)C)CC1 UACSRZWSADEYPK-UHFFFAOYSA-N 0.000 description 1
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 1
- LGVJIYCMHMKTPB-UHFFFAOYSA-N 3-hydroxynorvaline Chemical compound CCC(O)C(N)C(O)=O LGVJIYCMHMKTPB-UHFFFAOYSA-N 0.000 description 1
- COCMHKNAGZHBDZ-UHFFFAOYSA-N 4-carboxy-3-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]benzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(C([O-])=O)=CC=C1C(O)=O COCMHKNAGZHBDZ-UHFFFAOYSA-N 0.000 description 1
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 1
- STERIPGZVFHVJG-UHFFFAOYSA-N 6-chloro-2H-benzotriazol-4-ol Chemical compound OC1=CC(Cl)=CC2=C1N=NN2 STERIPGZVFHVJG-UHFFFAOYSA-N 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 101100080277 Caenorhabditis elegans ncr-1 gene Proteins 0.000 description 1
- 101100533230 Caenorhabditis elegans ser-2 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 108700006830 Drosophila Antp Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- NIGWMJHCCYYCSF-UHFFFAOYSA-N Fenclonine Chemical compound OC(=O)C(N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-UHFFFAOYSA-N 0.000 description 1
- 102100035857 Glutamate decarboxylase 2 Human genes 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000873786 Homo sapiens Glutamate decarboxylase 2 Proteins 0.000 description 1
- 108700020121 Human Immunodeficiency Virus-1 rev Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100037441 Intermediate conductance calcium-activated potassium channel protein 4 Human genes 0.000 description 1
- 101710087467 Intermediate conductance calcium-activated potassium channel protein 4 Proteins 0.000 description 1
- 108010011209 Kv1.1 Potassium Channel Proteins 0.000 description 1
- 102000014092 Kv1.1 Potassium Channel Human genes 0.000 description 1
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GDFAOVXKHJXLEI-VKHMYHEASA-N N-methyl-L-alanine Chemical compound C[NH2+][C@@H](C)C([O-])=O GDFAOVXKHJXLEI-VKHMYHEASA-N 0.000 description 1
- 101100459404 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) npc-1 gene Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010088535 Pep-1 peptide Proteins 0.000 description 1
- 241000283080 Proboscidea <mammal> Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 description 1
- RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000242730 Stichodactyla helianthus Species 0.000 description 1
- 241000187398 Streptomyces lividans Species 0.000 description 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
- 102000002933 Thioredoxin Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 description 1
- 229960004287 clofazimine Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002999 depolarising effect Effects 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 102000046611 human KCNA3 Human genes 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- SCIFESDRCALIIM-UHFFFAOYSA-N n-methylphenylalanine Chemical compound CNC(C(O)=O)CC1=CC=CC=C1 SCIFESDRCALIIM-UHFFFAOYSA-N 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007512 neuronal protection Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000002993 phenylalanine derivatives Chemical class 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 229940125422 potassium channel blocker Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 229960002718 selenomethionine Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- JPZXHKDZASGCLU-LBPRGKRZSA-N β-(2-naphthyl)-alanine Chemical compound C1=CC=CC2=CC(C[C@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-LBPRGKRZSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
Description
本出願は、2014年8月15日に出願された表題「新規なカリウムチャネルブロッカー」のオーストラリア特許仮出願第2014903189号の優先権を主張し、その内容の全体を参照により本明細書に組み込む。
以下の特許明細書を以下の説明において参照する:
表題「Kv1.3の選択的で強力なペプチド阻害剤」の国際公開第2010/108154号パンフレットの国際特許明細書。この特許明細書の内容は、全体を参照により本明細書に組み込む。
(I)a−X−4X−3X−2X−1−b(配列番号3)
[式中、X−4はD、E若しくはその他の負に荷電したアミノ酸又はそれらの誘導体であり、
X−3はE、I、L、S、V、W又はトリプトファン誘導体であり、
X−2は任意のアミノ酸であり、
X−1は任意のアミノ酸であり、
aは存在しないか、又は第1の付加部分(additional moiety)であり、
bは存在しないか、又は第2の付加部分(additional moiety)である]
によるアミノ酸配列を含むN末端伸長(N-terminal extension)とを含む、前記アナログを提供する。
(II)a−X−4X−3X−2X−1−b−[ShK毒素ポリペプチド]
の通りであってもよい。
RSCIDTIPKSRCTAFQCKHSMKYRLSFCRKTCGTC(配列番号4)。
(I)a−X−4X−3X−2X−1−b(配列番号3)
[式中、X−4はD、E若しくはその他の負に荷電したアミノ酸又はそれらの誘導体であり、
X−3はE、I、L、S、V、W又はトリプトファン誘導体であり、
X−2は任意のアミノ酸であり、
X−1は任意のアミノ酸であり、
aは存在しないか、又は第1の付加部分であり、
bは存在しないか、又は第2の付加部分である]
によるアミノ酸配列を含むN末端伸長とを含む、アナログを提供する。
(II)a−X−4X−3X−2X−1−b−[ShK毒素ポリペプチド]
の通りであってもよい。
RSCIDTKPKSRCTAFQCKHSMKYRLSFCRKTCGTC(配列番号11)
RSCIDTIPKARCTAFQCKHSMKYRLSFCRKTCGTC(配列番号12)
RSCIDTIPKSRCTAFKCKHSMKYRLSFCRKTCGTC(配列番号13)
RSCIDTIPKSRCTAFQCKHKMKYRLSFCRKTCGTC(配列番号14)
RSCIDTIPKSRCTAFQCKHRMKYRLSFCRKTCGTC(配列番号15)
RSCIDTIPKSRCTAFQCKHSMAYRLSFCRKTCGTC(配列番号16)
RSCIDTIPKSRCTAFQCKHSMKARLSFCRKTCGTC(配列番号17)
RSCIDTIPKSRCTAFQCKHSMKYRLSFCKKTCGTC(配列番号18)
EWSSRSCIDTIPKSRCTAFQCKHSMKYRLSFCRKTCGTC(配列番号10)
からなるポリペプチドである。
材料及び方法
分子モデリング−Kv1.3に結合したShKの誘導体の複合体のモデリングは、既に開発されたマウスKv1.3(mKv1.3)に結合したShK−192のモデル(Pennington MW et al., Mol Pharmacol 75:762-773 (2009))から開始した。このモデルは、鋳型としてストレプトマイセス・リビダンス(Streptomyces lividans)のK+チャネル(KcsA、PDBid 1BL8)のX線結晶構造を使用し、これにShK−192のモデルをドッキングさせた。ShKへのN末端伸長のループモデリングは、MODELLERプログラム(Eswar N et al., Curr Protoc Bioinformatics Chapter 5, Unit 5 6 (2006))を使用して実施した。各複合体について、25の初期モデルを作製し、これらのモデルそれぞれについて、25のループモデル(N末端伸長残基のみからなる)を考案し、全部で625のモデルをそれぞれの長さのN末端伸長について作製した。
ShKのN末端伸長のモデリング−Kv1.3に結合したShK−192のモデルにおいて、N末端の負に荷電したホスホノ基は、Kv1.3チャネルのLys411の側鎖アンモニウム基と塩架橋を形成することが予測された。ホスホノ基は、チャネルに対するこのアナログの高い親和性におそらく関与するが、免疫原になりやすい可能性も示され、その産生及びペプチドへの結合には化学合成が必要で、これらの問題はホスホノ基の代わりに標準アミノ酸を使用することによって克服することができるという仮説がたてられた。ShK−192との複合体におけるKv1.3の相同性モデルにおいて(図1A)、ホスホノ基はWT ShK毒素N末端から約8Åのところにあり、これはN末端と完全に伸長したGlu残基のカルボキシレートとの間の距離(約4.7Å)のほぼ2倍であることが見いだされた。したがって、必要な距離に届き、チャネルへの親和性を維持するために、ホスホノ基とそのリンカーの置き換えに2個以上のアミノ酸がおそらく必要であることが考えられた。
標準アミノ酸のみからなるN末端伸長を有する新規なShKアナログを調べた。これらのアナログのいくつかは、Kv1.1チャネルよりもKv1.3チャネルに対して選択性を示し、最も顕著なものはN末端のEWSS(配列番号2)テトラペプチド伸長を有するアナログである。この[EWSS]ShKアナログは、Kv1.1に対してごく弱い阻害を示すが、Kv1.3チャネルに対して高い効力を維持していた(IC50 33±7pM)。モデリング研究によって、EWSS(配列番号2)テトラペプチド伸長は、アナログShK−192におけるホスホノ部分と親水性リンカーについて予測されたKv1.3チャネルとの相互作用を模倣することができることが示唆された。テトラペプチド伸長はまた、ホスファターゼによる加水分解を受けにくい。本発明によるShKアナログは、当業者に周知の合成又は組換え技術を使用して産生することができる。これらは、全身性免疫抑制並びに標的外チャネル、特にKv1.1の阻害による心臓及び神経における毒性の可能性を回避しながら、自己免疫疾患の治療のための治療剤の基礎として大きな可能性を提供する。
Atkinson MA et al., Lancet 358:766 (2001)
Beeton C et al., J Biol Chem 278:9928-9937 (2003)
Beeton C et al., Proc Natl Acad Sci USA 103:17414-17419 (2006)
Beeton C et al., Inflamm Allergy Drug Targets 10:313-321 (2011)
Bennett J et al., J Neuroimmunol 229:180-191 (2010)
Berger T et al., New Engl J Med 349:139-145 (2003)
Chang SC et al., Toxicon 60:840-850 (2012)
Chi V et al., Toxicon 59:529-546 (2012)
Corcione A et al., Proc Natl Acad Sci USA 101:11064-11069 (2004)
Dorner T et al., Curr Opin Rheumatol 15:246-252 (2003)
Duan Y et al., J Comput Chem 24:1999-2012 (2003)
Eswar N et al., Curr Protoc Bioinformatics Chapter 5, Unit 5 6 (2006)
Fasth A et al., Scand J Immunol 60:199-208 (2004)
Fawell S et al., Proc Natl Acad Sci USA 91:664-668 (1994)
Friedrich M et al., Arch Dermatol Res 292:519-521 (2000)
Gilhar A et al., J Invest Dermatol 131:118-124 (2011)
Glasscock E et al., J Neurosci 30:5167-5175 (2010)
Grimmer S et al., Mol Pharmacol 45:1227-1234 (1994)
Gutman GA et al., Pharmacol Rev 57:473-508 (2005)
Hu LN et al., Plos One 8 (2013)
Kalman K et al., J Biol Chem 273:32697-32707 (1998)
Kim K-H et al., Biotechnol Bioprocess Eng 6:244-251 (2001)
Koch Hansen L et al., J Crohns Colitis 8(11):1378-91 (2014)
Kolb HC et al., Agnew Chem Int Ed Engl 40:2004-2021 (2001)
Koshy S et al., J Biol Chem 289:12623-12632 (2014)
Leanza L et al., Leukemia 27:1782-1785 (2013)
Leanza L et al., Cell Calcium 58:131-138 (2015)
Lepthien S et al., Proc Natl Acad Sci USA 105:16095-16100 (2008)
Lanigan MD et al., Biochemistry 41(40):11963-11971 (2002)
Liwo A et al., J Comput Chem 18:849-873 (1997)
Lovett-Racke AE et al., J Clin Invest 101:725-730 (1998)
Morris MC et al., Nat Biotechnol 19:1173-1176 (2001)
O’Connor KC et al., J Clin Immunol 21:81-92 (2001)
Okuyama M et al., Nat Methods 4(2):153-159 (2007)
Pennington MW et al., Mol Pharmacol 75:762-773 (2009)
Rauer H et al., J Biol Chem 274:21885-21892 (1999)
Ruben S et al., J Virol 63:1-8 (1989)
Sallusto F et al., Annu Rev Immunol 22:745-763 (2004)
Sharpless KB and R Manetsch, Expert Opin Drug Discov 7:489-501 (2012)
Shen JY et al., Nat Commun 4:2611 (2013)
Tarcha EJ et al., J Pharmacol Exp Ther 342:642-653 (2012)
Torchilin VP et al., J Liposome Res 3:201-255 (1993)
Tornoe CW et al., J Org Chem 67:3057-3064 (2002)
Tucker K et al., Int J Obes (Lond) 32(8):1222-1232 (2008)
Tudor JE et al., Nat Struct Biol 3:317-320 (1996)
Valverde P et al., J Dent Res 84(6):488-499 (2005)
Viglietta V et al., J Clin Invest 109:1511-1511 (2002)
Wagstaff KM and DA Jans, Curr Med Chem 13(12):1371-1387 (2006)
Wulff H et al., J Clin Invest 111:1703-1713 (2003)
Wulff H et al., J Immunol 173:776-786 (2004)
Xu J et al., Hum Mol Genet 12(5):551-559 (2003)
Xu J et al., Proc Natl Acad Sci USA 101(9):3112-3117 (2004)
Claims (18)
- スチコダクチラ・ヘリアンサス毒素ShKのアナログであって、ShK毒素ポリペプチドと、EWSS(配列番号2)、EWST(配列番号6)、EWTT(配列番号7)及びEWTS(配列番号8)からなる群から選択されるN末端伸長とを含む、前記アナログ。
- ShK毒素ポリペプチドが、RSCIDTIPKSRCTAFQCKHSMKYRLSFCRKTCGTC(配列番号4)に対応するアミノ酸配列を含む、請求項1に記載のアナログ。
- ShK毒素ポリペプチドが、Met21の置換を含むバリアントアミノ酸配列を含む、請求項1又は2に記載のアナログ。
- N末端伸長がEWSS(配列番号2)である、請求項1〜3のいずれかに記載のアナログ。
- Cys3〜Cys35、Cys12〜Cys28及びCys17〜Cys32の間にジスルフィド架橋を有するポリペプチドである、請求項1〜4のいずれかに記載のアナログ。
- さらに細胞透過性ペプチドを含む、請求項1〜5のいずれかに記載のアナログ。
- 請求項1〜6のいずれかに記載のアナログを含む、対象におけるTリンパ球又はクラススイッチされたB細胞の増殖の阻害剤であって、任意で薬学的に許容される担体と組み合わせて投与される、前記阻害剤。
- 請求項1〜6のいずれかに記載のアナログを含む、対象における自己免疫疾患の治療剤であって、 任意で薬学的に許容される担体と組み合わせて投与される、前記治療剤。
- 治療される自己免疫疾患が、TEM細胞によって媒介される自己免疫疾患である、請求項8に記載の治療剤。
- 自己免疫疾患の治療のための医薬品の調製における、請求項1〜6のいずれかに記載のアナログの使用。
- 治療される自己免疫疾患が、TEM細胞によって媒介される自己免疫疾患である、請求項10に記載の使用。
- 請求項1〜6のいずれかに記載のアナログを含む、対象におけるがんの治療剤であって、任意で薬学的に許容される担体と組み合わせて投与される、前記治療剤。
- がんが固形腫瘍、白血病又はリンパ腫である、請求項12に記載の治療剤。
- がんの治療のための医薬品の調製における、請求項1〜6のいずれかに記載のアナログの使用。
- がんが固形腫瘍、白血病又はリンパ腫である、請求項14に記載の使用。
- 請求項1〜6のいずれかに記載のアナログをコードするヌクレオチド配列を含むポリヌクレオチド分子。
- 請求項16に記載のポリヌクレオチド分子を含むクローニング又は発現ベクター。
- 請求項16に記載のポリヌクレオチド分子又は請求項17に記載のクローニング若しくは発現ベクターを含む宿主細胞であって、培養中にアナログを発現することができる、前記宿主細胞。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020081545A JP6953579B2 (ja) | 2014-08-15 | 2020-05-01 | 新規なカリウムチャネルブロッカー及び自己免疫疾患の治療におけるそれらの使用 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2014903189 | 2014-08-15 | ||
AU2014903189A AU2014903189A0 (en) | 2014-08-15 | Novel potassium channel blockers | |
PCT/AU2015/000487 WO2016023072A1 (en) | 2014-08-15 | 2015-08-14 | Novel potassium channel blockers and use thereof in the treatment of autoimmune diseases |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020081545A Division JP6953579B2 (ja) | 2014-08-15 | 2020-05-01 | 新規なカリウムチャネルブロッカー及び自己免疫疾患の治療におけるそれらの使用 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017525357A JP2017525357A (ja) | 2017-09-07 |
JP2017525357A5 JP2017525357A5 (ja) | 2018-09-20 |
JP6847828B2 true JP6847828B2 (ja) | 2021-03-24 |
Family
ID=55303691
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017508102A Active JP6847828B2 (ja) | 2014-08-15 | 2015-08-14 | 新規なカリウムチャネルブロッカー及び自己免疫疾患の治療におけるそれらの使用 |
JP2020081545A Active JP6953579B2 (ja) | 2014-08-15 | 2020-05-01 | 新規なカリウムチャネルブロッカー及び自己免疫疾患の治療におけるそれらの使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020081545A Active JP6953579B2 (ja) | 2014-08-15 | 2020-05-01 | 新規なカリウムチャネルブロッカー及び自己免疫疾患の治療におけるそれらの使用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US10246496B2 (ja) |
EP (1) | EP3180365B1 (ja) |
JP (2) | JP6847828B2 (ja) |
AU (1) | AU2015303825B2 (ja) |
WO (1) | WO2016023072A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102533290B1 (ko) * | 2022-04-14 | 2023-05-16 | 한국해양과학기술원 | 전압개폐 칼륨이온채널 억제 활성능을 갖는 펩타이드 |
KR102553070B1 (ko) * | 2022-06-16 | 2023-07-07 | 한국해양과학기술원 | 전압개폐 칼륨이온채널 억제 활성능을 갖는 작은상자해파리 기원 펩타이드 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005294124B2 (en) | 2004-10-07 | 2012-02-23 | Bachem Biosciences, Inc. | Analogs of ShK toxin and their uses in selective inhibition of Kv1.3 potassium channels |
PE20081140A1 (es) | 2006-10-25 | 2008-09-22 | Amgen Inc | Agentes terapeuticos a base de peptidos derivados de toxinas |
ATE537185T1 (de) * | 2007-05-14 | 2011-12-15 | Univ Mexico Nacional Autonoma | Vm23 und vm24, zwei skorpionpeptide, die humane t-lymphozyten-kaliumkanäle (untertyp kv1.3) mit hoher selektivität blockieren |
WO2010108153A2 (en) * | 2009-03-20 | 2010-09-23 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
TWI535455B (zh) * | 2011-06-06 | 2016-06-01 | 奇尼塔一有限責任公司 | 以shk為主之醫藥組合物及其製備方法及用途 |
PT2948559T (pt) * | 2013-01-25 | 2018-07-24 | Janssen Biotech Inc | ¿antagonistas de kv1.3 e métodos de utilização |
-
2015
- 2015-08-14 WO PCT/AU2015/000487 patent/WO2016023072A1/en active Application Filing
- 2015-08-14 JP JP2017508102A patent/JP6847828B2/ja active Active
- 2015-08-14 AU AU2015303825A patent/AU2015303825B2/en active Active
- 2015-08-14 EP EP15832619.9A patent/EP3180365B1/en active Active
- 2015-08-14 US US15/503,841 patent/US10246496B2/en active Active
-
2020
- 2020-05-01 JP JP2020081545A patent/JP6953579B2/ja active Active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102533290B1 (ko) * | 2022-04-14 | 2023-05-16 | 한국해양과학기술원 | 전압개폐 칼륨이온채널 억제 활성능을 갖는 펩타이드 |
KR102553070B1 (ko) * | 2022-06-16 | 2023-07-07 | 한국해양과학기술원 | 전압개폐 칼륨이온채널 억제 활성능을 갖는 작은상자해파리 기원 펩타이드 |
Also Published As
Publication number | Publication date |
---|---|
WO2016023072A1 (en) | 2016-02-18 |
EP3180365A4 (en) | 2018-01-17 |
AU2015303825B2 (en) | 2021-01-14 |
EP3180365B1 (en) | 2021-08-18 |
JP6953579B2 (ja) | 2021-10-27 |
US10246496B2 (en) | 2019-04-02 |
AU2015303825A1 (en) | 2017-03-23 |
JP2020127419A (ja) | 2020-08-27 |
US20170362286A1 (en) | 2017-12-21 |
JP2017525357A (ja) | 2017-09-07 |
EP3180365A1 (en) | 2017-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7280193B2 (ja) | 軟骨ホーミングペプチドコンジュゲート及びその使用方法 | |
AU2021212006B2 (en) | Modifications and uses of conotoxin peptides | |
JP6953579B2 (ja) | 新規なカリウムチャネルブロッカー及び自己免疫疾患の治療におけるそれらの使用 | |
TW201819398A (zh) | 治療性肽 | |
JP7306655B2 (ja) | Il-37バリアント | |
US20230414702A1 (en) | Compounds and pharmaceutical use thereof in the treatment of cancer | |
JP2022545916A (ja) | コンプスタチン類似体及びその医学的使用 | |
US20230090247A1 (en) | Molecules targeting ras protein | |
CN107106643B (zh) | 在癌症或癌转移的治疗或预防中的环状乙酰胆碱酯酶c端肽 | |
US20230391838A1 (en) | Conformationally-Constrained Alpha-RGIA Analogues | |
US20140155331A1 (en) | Novel high affinity bivalent helically constrained peptide against cancer | |
JP2012504409A (ja) | ソマトスタチン類似体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180806 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180806 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190808 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191107 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200501 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20200501 |
|
C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20200518 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20201113 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20201117 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210208 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210303 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6847828 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |